Pharma shifts focus from small molecules to biologics

In the last 5 years, big pharma has continued its move toward large molecules and biologics for drug development.  Two recent studies from Withers & Rogers (a UK law firm specializing in IP) and KMR Group (a pharma consultancy) report on some of the trends among...